Andrew J. Danielsen has been with Mayo Clinic Ventures (MCV) since 2002. He oversees the licensing, technology development, and business development functions of MCV. Collectively, these groups work to identify, develop, and commercialize Mayo Clinic intellectual property. In addition, MCV is also involved in managing a $100M venture and growth fund and a $5M seed fund. Mr. Danielsen received a B.S. in biochemistry and molecular biology from the University of Wisconsin-Eau Claire, his M.S. degree in molecular biology from the Mayo Graduate School of Medicine, and is a registered Patent Agent.
Will started his career in electoral politics as a field operative for national, state, and local campaigns. He is now co-founder and CCO of OpenTrons Labworks, a Y Combinator and Khosla Ventures backed start-up building lab robots for biologists. In the last two years Will has led the product and sales teams, and there are now OpenTrons in 96 labs around the world.
Dr. J. Fernando Bazan was appointed Chief Technology Officer when he joined the Company on August 1, 2013. Following training at Stanford, Berkeley, and UCSF in biochemistry and biophysics, he led very active groups in biotherapeutics discovery as a senior scientist at DNAX Research Institute (now Merck Research Labs) and at Genentech (Roche). He also served as Chief Scientific Officer at NeuroScience, a neuroimmunology diagnostics startup. Dr. Bazan holds an adjunct faculty appointment in the Dept. of Pharmacology at the University of Minnesota School of Medicine.
Dr. Traci Downs has over eighteen years of experience in functional neuroimaging and neuroscience with extensive work with functional magnetic resonance imaging (fMRI) and positron emission tomography (PET). Since 2005, she has been the President and Chief Operating Officer of Archinoetics where she achieved 400% growth in the first four years. From 2007 to 2011, she was the CEO of Fatigue Science, an Archinoetics spin-off company. Until 2011, she also served on the Board of Directors for the Hawaii Science & Technology Council. Previously, she has been a Program Manager of a research portfolio worth over $15M from government agencies, private industry, and non-profit organizations.
Matt Otterstatter brings a technical background from the rocket propulsion industry to Vilicus Ventures, having been both a program manager and senior engineer at Aerojet Rocketdyne. Matt is a Kauffman Fellow, which is a global program dedicated to spreading entrepreneurial best practices from Silicon Valley to the rest of the world. To date, the collective network of approximately 400 Kauffman Fellows has made over $6B in venture capital investments, sparking growth in hundreds of new enterprises and creating tens of thousands of jobs. Matt has built and run a startup accelerator in California and also serves as a Techstars mentor in the Sprint Mobile Health Accelerator.
Dr. Perry Hackett is a co-founder of Recombinetics and serves as Chair of its Scientific Advisory Board. He is co-founder of gene therapy company, Discovery Genomics, where he previously served as Chief Scientific Officer and Chairman. He is also a professor and research scientist in the University of Minnesota’s department of Genetics, Cell Biology and Development and co-founder of the Center for Genome Engineering. Hackett has a degree in Physics from Stanford University, a PhD in Biophysics and Genetics from the University of Colorado, and did postdoctoral training at the Max Planck Institute for Cell Biology in Germany and at the University of California in San Francisco.
Thomas J. Puff, Esq.
Thomas J. Puff, Esq. is a nationally recognized corporate, securities law, mergers and acquisitions and venture capital attorney. He led the Securities Law Groups as a Partner in two large national law firms prior to founding Venture Law (VLR). VLR serves as anoutside US Corporate Counsel and Mr. Puff is the Secretary to the Board. Mr. Puff has been involved in private placements, public offerings and debt and equity financing's in domestic and international transactions aggregating over 650 million in his career, including service to issuers such as Michael Foods Inc., Taser Int’l, Stellent (acquired by Oracle), Health Fitness Corporation, Super Solutions (acquired by Oracle), ProUroCare, Metamodix, Redstone American Grill and investors St. Paul Venture Capital, Crescendo Ventures, The Pohlad Family Office/Sahara Investment Corp. along with dozens of prominent US angel investors/CEO’s such as John Goodman, Dr. Glen Nelson/GDN Holdings, Phil Smith, Founder Taser Int’l, John Morrison, Carl Pohlad, Irwin Jacobs, William Beddor and many others.